Skip to content
DataLookout
Menu

NCT07194980

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 10 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 15, 2026 to Dec 1, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 60 words
    • Secondary endpoints: details revised at 9 of 12 entries
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Notable Start date: Sep 1, 2026 to Oct 15, 2026
    • Eligibility criteria expanded, about 22 words
    • Site contact updated
    v11
  3. Notable Start date: Aug 1, 2026 to Sep 1, 2026v10
  4. Notable Start date: Jul 1, 2026 to Aug 1, 2026v9
  5. Notable Start date: May 29, 2026 to Jul 1, 2026v8
  6. Notable Recruitment opened
    • Start date: Jul 1, 2026 to May 29, 2026
    • Site details revised
    v6
  7. Notable Start date: Apr 1, 2026 to Jul 1, 2026v4
  8. Notable Start date: Dec 2025 to Apr 1, 2026v3
  9. Notable Start date: Oct 2025 to Dec 2025v2
  10. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Complete response (CR)
Timeframe: Up to 5 years after completion of study treatment

Secondary (12)

Overall response rate
Overall survival (OS)
Progression free survival (PFS)
Time to response (TTR)
Time to next treatment (TTNT)
Show 7 moreShow less
Duration of response (DoR)
CR on positron emission tomography/computed tomography by Lugano criteria
Incidence of adverse events
Incidence of dose-limiting toxicity (DLT)
Incidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity (ICANS)
Time to CRS or ICANS onset
Time from CRS or ICANS onset to resolution

Arms and interventions

Treatment (nemtabrutinib, lisocabtagene maraleucel)Experimental

Patients receive nemtabrutinib PO daily on days 1-28 of each cycle (NOTE: nemtabrutinib is not given during lymphodepleting therapy). Cycles repeat every 28 days for up to 1 year after lisocabtagene maraleucel infusion in the absence of disease progression or unacceptable toxicity. Patients undergo leukapheresis 7 days after start of nemtabrutinib treatment. Patients receive SOC lymphodepleting therapy consisting of cyclophosphamide IV and fludarabine IV on approximately the 5th, 4th, and 3rd day prior to lisocabtagene maraleucel infusion. Patients then receive lisocabtagene maraleucel IV 36-96 hours after completion of SOC lymphodepleting therapy. Patients also undergo TTE or MUGA during screening, and PET/CT scans, bone marrow biopsy and aspiration, lymph node biopsy, and blood sample collection throughout the study.

Drugs: Nemtabrutinib

Biologicals: Lisocabtagene Maraleucel

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States